Top Story

Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease

December 17, 2014

An analysis of genomic rearrangements detected by a diagnostic lineage test helped determine whether multiple non–small cell lung cancer tumors were independent primary tumors or sites of metastatic disease, according to study results.

“Unfortunately, distinguishing between independent primary tumors and metastasis is a frequent dilemma for pathologists,” researcher Marie-Christine Aubry, MD, a pathologist at Mayo Clinic in Rochester, Minn., said in a press release. “We need better tests to help the clinician match the treatment approach to the patient’s individual needs.”

FDA approvals

FDA expands approval of Cyramza to include aggressive NSCLC

December 17, 2014
The FDA expanded the approved use of ramucirumab to include use in combination with docetaxel for second-line treatment of patients with metastatic non–small cell…
In the Journals

Second-line SBRT plus erlotinib extended survival in advanced NSCLC

December 15, 2014
Treatment with stereotactic body radiation therapy and erlotinib appeared highly effective in patients with metastatic stage IV non–small cell lung cancer who…
Richard Pazdur, MD FDA approvals

FDA expands approval of ramucirumab to treat aggressive NSCLC

December 12, 2014
The FDA today announced the expanded approval of ramucirumab in the treatment of patients with metastatic non–small cell lung cancer.Ramucirumab (Cyramza, Eli…
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease In the Journals

Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease

December 17, 2014
An analysis of genomic rearrangements detected by a diagnostic lineage test helped determine whether multiple non–small cell lung cancer tumors…
FDA approvals

FDA expands approval of Cyramza to include aggressive NSCLC

December 17, 2014
The FDA expanded the approved use of ramucirumab to include use in combination with docetaxel for second-line treatment of patients with metastatic…
In the Journals

Second-line SBRT plus erlotinib extended survival in advanced NSCLC

December 15, 2014
Treatment with stereotactic body radiation therapy and erlotinib appeared highly effective in patients with metastatic stage IV non–small cell…
Richard Pazdur, MD FDA approvals

FDA expands approval of ramucirumab to treat aggressive NSCLC

December 12, 2014
The FDA today announced the expanded approval of ramucirumab in the treatment of patients with metastatic non–small cell lung…
In the Journals

Lobectomy superior to sublobar resection for elderly patients with early-stage NSCLC

December 5, 2014
Lobectomy conferred better outcomes than sublobar resection in elderly patients with early-stage non-small cell lung cancer, according to results of…
In the Journals

Crizotinib superior to chemotherapy in advanced, ALK-positive NSCLC

December 3, 2014
Patients with advanced, ALK-positive non–small cell lung cancer who received first-line treatment with crizotinib demonstrated improved outcomes…
In the Journals

Thoracic radiotherapy improved outcomes in extensive-stage SCLC

December 1, 2014
The addition of thoracic radiotherapy to prophylactic cranial radiation significantly extended survival among patients with extensive-stage…
Peter J. Mazzone, MD, FCCP Meeting News Coverage

Serum metabolites may serve as biomarker for early lung cancer detection

November 26, 2014
Serum metabolite profiles significantly differed between patients with stage I to III non–small cell lung cancer and at-risk adults without…
Meeting News Coverage

Biopsies more costly, less effective in lung cancer diagnosis

November 25, 2014
Biopsies were identified as the most costly tests in lung cancer diagnosis, with negative biopsies accounting for 43.1% of total diagnostic costs…
Meeting News Coverage

Postoperative radiation extended survival in resected NSCLC

November 24, 2014
Postoperative radiotherapy improved survival by approximately 4 months in patients with resected non–small cell lung cancer with pathologically…
More Headlines »
morganatic-roan
morganatic-roan